Chung Jane 4
4 · SUTRO BIOPHARMA, INC. · Filed Dec 16, 2025
Insider Transaction Report
Form 4
Chung Jane
DirectorChief Executive Officer
Transactions
- Exercise/Conversion
Common Stock
2025-12-12+2,500→ 14,785 total - Tax Payment
Common Stock
2025-12-12$8.02/sh−894$7,165→ 13,891 total - Exercise/Conversion
Restricted Stock Unit (RSU)
2025-12-12−2,500→ 5,000 totalExp: 2027-12-01→ Common Stock (2,500 underlying)
Footnotes (3)
- [F1]Represents the number of shares of Common Stock that have been withheld by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of RSUs; does not represent a sale by the reporting person.
- [F2]Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.
- [F3]The RSU award vested or vests as to 1/4th of the total award annually, subject to continued service through each vesting date, with the first tranche vested on December 1, 2024. The reported transaction represents the deferred vesting and settlement of a tranche of this award pursuant to the terms of the reporting person's award agreement with the Issuer.